Defining critical quality attributes for monoclonal antibody therapeutic products

BioPharm International

Volumn 27, Issue 7, 2015, Pages 34-43

  Rathore, Anurag S ^a   Weiskopf, Andrew ^b   Reason, Andrew J ^c  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b BIOGEN   (United States)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; MONOCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRITICAL QUALITY ATTRIBUTE; IMMUNOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; PEPTIDE MAPPING; PHYSICAL CHEMISTRY; PRODUCT PARAMETERS; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RISK ASSESSMENT; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION;

EID: 84915770463     PISSN: 1542166X     EISSN: 19391862     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (11)

1. ICH, ICH Harmonized Tripartite Guideline Q8: Pharmaceutical Development, Step 4 version (August 2009).
2. A. S. Rathore, Trends Biotechnol. 27 (12) 698-705 (2009).
3. A. S. Rathore and H. Winkle, Nature Biotechnol. 27 (1) 26-34 (2009).
4. A. S. Rathore, Trends Biotechnol. 27 (9) 546-553 (2009).
5. ICH, ICH Harmonized Tripartite Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), Step 3 version (September 2011).
6. EMA, Guideline on Development, Production, Characterization and Specifications for Monoclonal Antibodies and Related Products, EMEA/CHMP/BWP/157653/2007 (December 2008).
7. ICH, ICH Topic Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Step 5 version (September 1999).
8. R.J. Seely and J. Haury, “Applications of Failure Modes and Effects Analysis to Biotechnology Manufacturing Processes” in Process Validation in Manufacturing of Biopharmaceuticals, A.S. Rathore and G. Sofer, Eds. Taylor & Francis (2005) pp 13-30.
9. CMC Biotech Working Group, A-Mab: A Case Study in Bioprocess Development. October 2009, www.casss.org/associations/9165/files/A-Mab_Case_Study_Version_2-1.pdf, accessed June 5, 2014.
10. S. Kozlowski, “Implementation Activities for QbD: FDA Office of Biotechnology Products,” presentation at 2010 WCBP CMC Strategy Forum (Bethesda, MD, 2010).
11. L. Zang, X. L. Hronowski, Y. Lyubarskaya, A. Buko, H. Madden, W. Meier, R. Mhatre, “LC–ESI/MS and MALDI-MS for Monitoring of Glycoform-Related Clearance of a Complex Glycoprotein in Cynomolgus Monkeys,” presentation at the 58th ASMS Conference on Mass Spectrometry (Salt Lake City, UT, 2010).